Why Is TRAVERE THERAPEUTICS (TVTX) Stock Up Today?

Why TVTX stock is up today

Travere Therapeutics stock rose 14.21% to $63.98 in premarket trading on August 5, 2026, driven by strong performance in its FILSPARI product and positive earnings call commentary. The stock opened with a 14.1% gap up from the previous close of $56.02, reaching a session high of $64.50 shortly after the market opened. The move followed the company's Q2 2026 earnings call, which highlighted robust demand for FILSPARI and a peak annual sales potential of more than $3 billion.

What Happened

The stock’s sharp rise came after Travere Therapeutics reported a Q2 2026 earnings call that outlined strong performance for FILSPARI, including a successful FSGS launch that exceeded expectations. The company also provided a revenue update of $141 million and a peak sales outlook of $3 billion. These details were included in a Form 8-K filing on August 4, which outlined the company's financial results and operational highlights. The report noted Travere’s Q2 2026 net loss of $34.8 million and cash and securities of $489.2 million, with HARMONY topline data expected in the second half of 2027.

What The Data Shows

The stock opened at $63.92 and traded as high as $64.50 before settling at $63.98. The session saw a volume of 0.5 million shares, which is 0.2 times the 3-month daily average. The 52-week range for Travere is $15.42 to $60.10, meaning the current price is above its 52-week high. The company has a market cap of $5.1 billion and remains unprofitable, with an EPS TTM of -0.51 and a net margin of -4.0%. Recent insider transactions include three sales totaling $867,000 over the past 90 days.

What To Watch

Travere Therapeutics will need to maintain strong operational performance and deliver on its FILSPARI and HARMONY program expectations to sustain investor confidence. The next key milestone will be the HARMONY topline data in the second half of 2027.